PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

Despite overlapping pathological features, uterine and gastrointestinal stromal tumors differ clinically. Surgery is the primary treatment; comprehensive preoperative imaging and postoperative pathological examination are critical to prevent misdiagnosis and optimize management.

Achieving meaningful survival benefit for patients with DMG requires a multidisciplinary approach bridging neuro-oncology, advanced imaging, and nanomaterials development. Future research must prioritize four key areas: (1) optimizing NP properties for superior brainstem penetration, (2) leveraging DMG-specific markers for active delivery, (3) integrating theranostics for real-time monitoring, and (4) developing scalable, clinically compliant manufacturing.

GALNT7-mediated O-GalNAc glycosylation stabilizes KIT and drives GIST progression. GALNT7 may serve as a prognostic biomarker and therapeutic target in GIST.

These findings suggest that a subset of morphologically defined cerebellar glioblastomas in adults represents the dpHGG, H3-/IDH-WT, RTK1 subtype. Recognition of this underappreciated manifestation is important for accurate tumor classification, and further accumulation of well-characterized cases is required to clarify its clinical significance.

These findings identify stromal CD81 expression as a novel prognostic marker in invasive breast cancer and highlight its association with a tumor-suppressive immune microenvironment, distinct from the immunosuppressive phenotype typically associated with PDPN-positive CAFs.

Lastly, our biochemical data were validated using imatinib response data for first-line metastatic disease; patients with predicted exon 18 sensitive mutations had longer progression-free survival than patients with predicted imatinib-resistant mutations. These results provide key evidence that should be used to guide therapy selection for PDGFRA-mutant GIST.

Esophageal GISTs are exceptionally rare, and those driven by BRAF gene fusions are even more uncommon. This report describes a 69-year-old woman who underwent surgical resection of an esophageal GIST harboring an MKRN1-BRAF gene fusion, offering insight into future treatment and surveillance strategies.

This study developed and validated a robust LRGS for MSS GC. This signature facilitates accurate prognosis prediction and shows potential to predict responses to both chemotherapy and immunotherapy.

For therapeutic categories, performance reached 0.84 for avapritinib sensitivity and 0.81 for imatinib sensitivity. Prognostic performance was comparable to pathology-based scores, with highest discrimination in the overall cohort and in patients without adjuvant therapy. DL applied to WSIs enables prediction of molecular alterations, treatment sensitivity, and RFS in GIST, performing comparably to established risk scores across international cohorts, providing a baseline for future multimodal predictors.

Clinically, two patients died within 3-9 months, while one remains clinically stable despite radiological progression. DHG-H3 K27 represents a rare hemispheric glioma subgroup sharing molecular and epigenetic features of DMG-H3 K27 without midline involvement, underscoring biological heterogeneity and the importance of integrated molecular classification.

WT GISTs exhibit considerable molecular heterogeneity with novel or rare mutations of uncertain significance. Targeted NGS enables the detection of clinically relevant alterations that may guide future diagnostic and therapeutic strategies. Our findings emphasize the importance of targeted molecular profiling and raise the potential for personalized treatment in this challenging subset of GISTs.

Together, these findings identify AKR1C3 as a candidate functional target of cypermethrin and suggest that AKR1C3 may be involved, at least in part, in cypermethrin-induced CRC-relevant cellular injury and oxidative stress. This study provides an exploratory framework for identifying exposure-related molecular targets linking foodborne pesticide residues to CRC-associated biological alterations.